NASDAQ:JAGX - Jaguar Health Stock Price, News & Analysis

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Jaguar Health Inc (NASDAQ:JAGX) released its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.10. The biotechnology company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.10 million. Jaguar Health had a negative return on equity of 698.61% and a negative net margin of 727.27%. View Jaguar Health's Earnings History.

Jaguar Health is scheduled to release their next quarterly earnings announcement on Monday, November 18th 2019. View Earnings Estimates for Jaguar Health.

2 brokerages have issued 1-year price targets for Jaguar Health's stock. Their predictions range from $5.00 to $10.00. On average, they expect Jaguar Health's share price to reach $7.50 in the next year. This suggests a possible upside of 424.5% from the stock's current price. View Analyst Price Targets for Jaguar Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

Media coverage about JAGX stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jaguar Health earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Jaguar Health.

Jaguar Health saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 199,100 shares, an increase of 178.5% from the July 31st total of 71,500 shares. Based on an average daily volume of 846,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 10.1% of the shares of the company are short sold. View Jaguar Health's Current Options Chain.

Some companies that are related to Jaguar Health include Syndax Pharmaceuticals (SNDX), Aeglea Bio Therapeutics (AGLE), Aratana Therapeutics (PETX), Xenon Pharmaceuticals (XENE), Spero Therapeutics (SPRO), CannTrust (CTST), Mirum Pharmaceuticals (MIRM), Calithera Biosciences (CALA), Athersys (ATHX), Chiasma (CHMA), Five Prime Therapeutics (FPRX), Molecular Templates (MTEM), Affimed (AFMD), Kamada (KMDA) and Ocular Therapeutix (OCUL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Conatus Pharmaceuticals (CNAT), Biopharmx (BPMX), Cara Therapeutics (CARA), Cascadian Therapeutics (CASC), PTC Therapeutics (PTCT), Neovasc (NVCN), Precipio (PRPO), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN) and Viking Therapeutics (VKTX).

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Jaguar Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Invesco Ltd. (0.51%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View Institutional Ownership Trends for Jaguar Health.

JAGX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd.. View Insider Buying and Selling for Jaguar Health.

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JAGX stock can currently be purchased for approximately $1.43.

Jaguar Health has a market capitalization of $66.30 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.